Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIB-626 in Friedreich's Ataxia
NCT04817111Phase 2Completed
- Sponsor
- Metro International Biotech
- Start
- May 2021
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of liposomal β-nicotinamide mononucleotide in Friedreich ataxia (FA), sponsored by Metro International Biotech. Started May 2021; status: completed.
02
Drugs
liposomal β-nicotinamide mononucleotide
03
Conditions
Friedreich ataxia (FA)
Beyond the preview
Go deeper on NCT04817111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04817111.